Arsenic agent shuts down 2 hard-to-treat cancers in animal experiments
Monday, January 3, 2011 - 12:20
in Health & Medicine
Researchers at the Georgetown Lombardi Comprehensive Cancer Centre, a part of Georgetown University Medical Centre, have found that an arsenic-based agent already FDA-approved for a type of leukaemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant paediatric brain cancer...